Alphamab Oncology
9966.HK News Today: Stay Updated with the Latest Alphamab Oncology News in Real Time
Find 9966.HK news now at Meyka AI. Stay informed with the latest Alphamab Oncology stocks updates, including price news, market analysis, and expert insights.
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 18, 2026
Cowen maintained a Buy on AstraZeneca. Read the AZN analyst rating update, implications, and Meyka AI grade
Market closed CHF42.54: BMY.SW stock shows oversold bounce potential
BMY.SW stock closed at CHF42.54 after a -4.40% drop; oversold bounce setup, Meyka grade and CHF39.34 forecast
Centessa Shares Soar Following Lilly’s $6.3B Acquisition Announcement
The stock market reacted strongly after a major acquisition announcement involving Centessa Shares. Eli Lilly, one of the largest pharmaceutical companies in the world, confirmed it will acquire Centessa Pharmaceuticals for $6.3 billion in an all‑cash deal. This news caused Centessa Shares to surge sharply, making the acquisition one of the most talked‑about deals in…
MAAT.PA MaaT Pharma SA (EURONEXT) down 19% intraday: support near €5.14
Intraday: MAAT.PA stock falls 19% to €5.24 on EURONEXT; volume 200,459. Short-term support and Meyka AI forecast included.
BNTX Stock Today: March 31: ELCC Cancer Data Steady Amid Biotech Rout
BioNTech stock holds near $85 as biotech volatility hits peers. ELCC cancer data on gotistobart showed 54% lower death risk in advanced lung cancer, supporting medium-term catalysts for German traders
BNTX Stock Today: March 30 — ELCC Data Show 54% Lower Death Risk
BioNTech stock: ELCC 2026 data show 54% lower death risk in advanced lung cancer. What it means for German investors, valuation, catalysts, and technicals.
Novartis to Acquire U.S. Biotech Firm Excellergy in Deal Worth Up to $2 Billion
Swiss pharmaceutical giant Novartis announced plans to acquire the U.S. biotech company Excellergy in a major strategic deal valued at up to $2 billion. The acquisition aims to expand Novartis’s drug development pipeline and strengthen its position in innovative therapies. Market watchers believe the transaction could have significant effects on the broader stock market and…
Merck Close to $6 Billion Deal to Acquire Terns Pharma, FT Says
Global pharmaceutical giant Merck is reportedly nearing a major acquisition worth nearly $6 billion, according to a Financial Times report. The deal involves U.S.-based biotech company Terns Pharmaceuticals and reflects a broader shift in the healthcare industry as large drugmakers race to strengthen their future drug pipelines. The potential acquisition has already sparked strong reactions…
GILD.SW Gilead (SIX) +73.91% pre-market CHF114.78 25 Mar 2026: what to watch
Pre-market GILD.SW stock jumps to CHF114.78 on 25 Mar 2026; Meyka grade, drivers and a CHF135.00 12-month forecast